REG - Hikma Pharmaceutical - Director/PDMR Shareholding
RNS Number : 3791QHikma Pharmaceuticals Plc25 February 2021
Hikma Pharmaceuticals PLC - EIP Awards
LONDON, 25 February 2021: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK)
(LEI: 549300BNS685UXH4JI75) announces that the Remuneration Committee made the following conditional awards under the Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company.Awards under the EIP were made on 25 February 2021 at a price of 2,525 pence per Ordinary Share (being the average price for the 30-day period prior to 31 December 2020, in accordance with the EIP rules) as follows:
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Said Darwazah
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Said Darwazah
2
Reason for the notification
a)
Position/status
Executive Chairman
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 34,827
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Said Darwazah
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Said Darwazah
2
Reason for the notification
a)
Position/status
Executive Chairman
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 19,830
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Sigurdur Olafsson
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Sigurdur Olafsson
2
Reason for the notification
a)
Position/status
Chief Executive Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 41,527
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Sigurdur Olafsson
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Sigurdur Olafsson
2
Reason for the notification
a)
Position/status
Chief Executive Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 24,836
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Mazen Darwazah
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Mazen Darwazah
2
Reason for the notification
a)
Position/status
Executive Vice Chairman
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 24,319
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Mazen Darwazah
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Mazen Darwazah
2
Reason for the notification
a)
Position/status
Executive Vice Chairman
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 13,903
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Bassam Kanaan
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Bassam Kanaan
2
Reason for the notification
a)
Position/status
EVP, Corporate Development and M&A
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 17,307
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Bassam Kanaan
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Bassam Kanaan
2
Reason for the notification
a)
Position/status
EVP, Corporate Development and M&A
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 13,378
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Khalid Nabilsi
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Khalid Nabilsi
2
Reason for the notification
a)
Position/status
Chief Financial Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 17,390
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Khalid Nabilsi
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Khalid Nabilsi
2
Reason for the notification
a)
Position/status
Chief Financial Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 13,927
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Riad Mishlawi
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Riad Mishlawi
2
Reason for the notification
a)
Position/status
President, Injectables
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 20,285
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Riad Mishlawi
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Riad Mishlawi
2
Reason for the notification
a)
Position/status
President, Injectables
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 17,120
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Majda Labadi
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Majda Labadi
2
Reason for the notification
a)
Position/status
EVP, Organisational Development
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 11,205
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Majda Labadi
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Majda Labadi
2
Reason for the notification
a)
Position/status
EVP, Organisational Development
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 8,662
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Susan Ringdal
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Susan Ringdal
2
Reason for the notification
a)
Position/status
EVP, Strategic Planning and Global Affairs
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 8,813
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Susan Ringdal
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Susan Ringdal
2
Reason for the notification
a)
Position/status
EVP, Strategic Planning and Global Affairs
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 6,812
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Brian Hoffmann
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Brian Hoffmann
2
Reason for the notification
a)
Position/status
President, US Generics
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 12,119
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Brian Hoffmann
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Brian Hoffmann
2
Reason for the notification
a)
Position/status
President, US Generics
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 10,227
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Henriette Nielsen
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Henriette Nielsen
2
Reason for the notification
a)
Position/status
EVP, Business Operations
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 14,374
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Henriette Nielsen
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Henriette Nielsen
2
Reason for the notification
a)
Position/status
EVP, Business Operations
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 12,130
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Shahin Fesharaki
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Shahin Fesharaki
2
Reason for the notification
a)
Position/status
Chief Scientific Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 14,972
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Shahin Fesharaki
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Shahin Fesharaki
2
Reason for the notification
a)
Position/status
Chief Scientific Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 11,574
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Hussein Arkhagha
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Hussein Arkhagha
2
Reason for the notification
a)
Position/status
Chief Counsel
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 7,867
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Hussein Arkhagha
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Hussein Arkhagha
2
Reason for the notification
a)
Position/status
Chief Counsel
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)
Price(s) and volume(s)
Price(s): £25.25
Volume(s): 5,245
d)
Aggregated information
N/A
e)
Date of the transaction
25 February 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHBBGDDRUDDGBU
Recent news on Hikma Pharmaceuticals
See all newsREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Hikma appoints new President of Generics business
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Block listing Interim Review
AnnouncementREG - Hikma Pharmaceutical - Annual Financial Report and Notice of AGM
Announcement